Exagen (Exagen) Total Liabilities : $30.82 Mil (As of Mar. 2024)

View and export this data going back to 2019. Start your Free Trial

What is Exagen Total Liabilities?

Exagen's Total Liabilities for the quarter that ended in Mar. 2024 was $30.82 Mil.

Exagen's quarterly Total Liabilities increased from Sep. 2023 ($33.42 Mil) to Dec. 2023 ($34.25 Mil) but then declined from Dec. 2023 ($34.25 Mil) to Mar. 2024 ($30.82 Mil).

Exagen's annual Total Liabilities increased from Dec. 2021 ($38.51 Mil) to Dec. 2022 ($43.76 Mil) but then declined from Dec. 2022 ($43.76 Mil) to Dec. 2023 ($34.25 Mil).

Exagen Total Liabilities Historical Data

The historical data trend for Exagen's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Exagen Total Liabilities Chart

Exagen Annual Data

Trend

Dec13

Dec14

Dec15

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Liabilities

Get a 7-Day Free Trial

32.65

36.54

38.51

43.76

34.25

Exagen Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Total Liabilities	Get a 7-Day Free Trial															43.30	32.28	33.42	34.25	30.82

Exagen Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Exagen's Total Liabilities for the fiscal year that ended in Dec. 2023 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	11.902	+	(21.991	+	0.357
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	0)
	=	34.25

Total Liabilities	=	Total Assets (A: Dec. 2023 )	-	Total Equity (A: Dec. 2023 )
	=	56.944	-	22.694
	=	34.25

Exagen's Total Liabilities for the quarter that ended in Mar. 2024 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	8.783	+	(21.766	+	0.268
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	0)
	=	30.82

Total Liabilities	=	Total Assets (Q: Mar. 2024 )	-	Total Equity (Q: Mar. 2024 )
	=	50.808	-	19.991
	=	30.82

Exagen Total Liabilities Related Terms

Thank you for viewing the detailed overview of Exagen's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Exagen (Exagen) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Exagen Inc (NAS:XGN) » Definitions » Total Liabilities

Comparable Companies

Traded in Other Exchanges

E08A:Germany

Address

1261 Liberty Way, Vista, CA, USA, 92081

Website

https://www.exagen.com

Exagen Inc is a commercial-stage diagnostics company committed to addressing the unmet need for the accurate diagnosis and monitoring of patients affected by autoimmune rheumatic diseases. It currently markets ten testing products under its Avise brand to provide an accurate, timely, and differential diagnosis and to optimize the treatment of ARDs. It markets and sells solutions to community rheumatologists.

Executives

John Aballi	director, officer: President and CEO	C/O DECIPHER BIOSCIENCES, INC., 6925 LUSK BLVD, SUITE 200, SAN DIEGO CA 92121
Paul Kim	director	4399 SANTA ANITA AVE, EL MONTE CA 91731
Tullis Growth Fund Ii, L.p.	10 percent owner	11770 US HWY 1, STE 503, PALM BEACH GARDENS FL 33408
Kamal Adawi	officer: Chief Financial Officer	C/O EXAGEN INC., 1261 LIBERTY WAY, SUITE C, VISTA CA 92131
Mark Hazeltine	officer: Chief Operating Officer	C/O EXAGEN INC., 1261 LIBERTY WAY, SUITE C, VISTA CA 92081
Wendy S. Johnson	director	800 E. LEIGH STREET, SUITE 209, RICHMOND VA 21219
Tullis James L L	director, 10 percent owner	100 FIRST STAMFORD PLACE, STAMFORD CT 06907
Ana Hooker	director	441 CHARMANY DRIVE, MADISON WI 53719
Frank Stokes	director	C/O CASTLE BIOSCIENCES, 820 S. FRIENDSWOOD DRIVE, SUITE 201, FRIENDSWOOD TX 77546
Hunt Holdings Limited Partnership	10 percent owner	C/O EXAGEN INC., 1261 LIBERTY WAY, SUITE C, VISTA CA 92081
Nmsic Co-investment Fund, L.p.	10 percent owner	C/O EXAGEN INC., 1261 LIBERTY WAY, SUITE C, VISTA CA 92081
Debra Zack	officer: Chief Medical Officer	C/O EXAGEN, INC., 1261 LIBERTY WAY, SUITE C, VISTA CA 92081
H.i.g. Bio-exagen, L.p.	10 percent owner	C/O EXAGEN INC., 1261 LIBERTY WAY, SUITE C, VISTA CA 92081
Thierry Dervieux	officer: Chief Scientific Officer	C/O EXAGEN DIAGNOSTICS, INC., 1261 LIBERTY WAY, VISTA CA 92081
Nmsic Focused Llc	10 percent owner	C/O EXAGEN INC., 1261 LIBERTY WAY, SUITE C, VISTA CA 92081